Marshall Wace
PCRX icon

Marshall Wace’s Pacira BioSciences PCRX Stock Holding History

Marshall Wace’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,366
Closed -$4.55M – 3278
2025
Q2 		$4.55M Buy
+190,366
New +$4.8M 0.01% 1187
2025
Q1 		– Sell
-42,613
Closed -$803K – 2976
2024
Q4 		$803K Sell
42,613
-482,336
-92% -$8.47M ﹤0.01% 1832
2024
Q3 		$7.9M Sell
524,949
-446,194
-46% -$7.63M 0.01% 845
2024
Q2 		$27.8M Buy
971,143
+159,791
+20% +$4.55M 0.04% 401
2024
Q1 		$23.7M Buy
811,352
+331,159
+69% +$10.2M 0.04% 458
2023
Q4 		$16.2M Sell
480,193
-5,452
-1% -$160K 0.03% 539
2023
Q3 		$14.9M Buy
485,645
+97,348
+25% +$3.51M 0.03% 516
2023
Q2 		$15.6M Buy
388,297
+69,136
+22% +$2.86M 0.03% 572
2023
Q1 		$13M Buy
319,161
+193,804
+155% +$7.71M 0.03% 615
2022
Q4 		$4.84M Buy
125,357
+82,396
+192% +$4.01M 0.01% 1207
2022
Q3 		$2.29M Buy
42,961
+24,638
+134% +$1.37M 0.01% 1918
2022
Q2 		$1.07M Buy
+18,323
New +$1.2M ﹤0.01% 2405
2022
Q1 		– Sell
-205,322
Closed -$12.4M – 3854
2021
Q4 		$12.4M Buy
205,322
+190,381
+1,274% +$10.5M 0.02% 721
2021
Q3 		$837K Buy
+14,941
New +$861K ﹤0.01% 2124
2021
Q2 		– Sell
-30,624
Closed -$2.15M – 2974
2021
Q1 		$2.15M Buy
+30,624
New +$2.19M 0.01% 1292
2020
Q1 		– Sell
-19,673
Closed -$891K – 1956
2019
Q4 		$891K Sell
19,673
-253,489
-93% -$10.8M 0.01% 1014
2019
Q3 		$10.4M Buy
+273,162
New +$10.9M 0.08% 282
2016
Q4 		– Sell
-10,749
Closed -$368K – 1090
2016
Q3 		$368K Buy
+10,749
New +$421K ﹤0.01% 835
2015
Q4 		– Sell
-54,226
Closed -$2.23M – 1087
2015
Q3 		$2.23M Buy
+54,226
New +$3.32M 0.03% 426

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's PCRX Position: Q3 2025 in Review

Marshall Wace sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 190,366 shares — an estimated $4.55M sold.

Marshall Wace first reported a position in PCRX in Q3 2015 and held it in 19 quarters. The position peaked at $27.8M in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

  • Marshall Wace reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 190,366 Pacira BioSciences shares in Q3 2025, an estimated $4.55M.
  • Marshall Wace first reported a position in Pacira BioSciences in Q3 2015 and held it in 19 quarters.
  • Marshall Wace's Pacira BioSciences position peaked at $27.8M in Q2 2024.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.